Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus
- Title
- Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus
- Author
- 양철수
- Keywords
- drug resistance; LCB01-0371; Mycobacterium abscessus; oxazolidinone
- Issue Date
- 2017-08
- Publisher
- AMER SOC MICROBIOLOGY
- Citation
- ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v. 61, no. 9, Article no. e02752-16
- Abstract
- Mycobacterium abscessus is a highly pathogenic drug-resistant rapidly growing mycobacterium. In this study, we evaluated the in vitro, intracellular, and in vivo activities of LCB01-0371, a novel and safe oxazolidinone derivative, for the treatment of M. abscessus infection and compared its resistance to that of other oxazolidinone drugs. LCB01-0371 was effective against several M. abscessus strains in vitro and in a macrophage model of infection. In the murine model, a similar efficacy to linezolid was achieved, especially in the lungs. We induced laboratory-generated resistance to LCB01-0371; sequencing analysis revealed mutations in rplC of T424C and G419A and a nucleotide insertion at the 503 position. Furthermore, LCB01-0371 inhibited the growth of amikacin-, cefoxitin-, and clarithromycin-resistant strains. Collectively, our data indicate that LCB01-0371 might represent a promising new class of oxazolidinones with improved safety, which may replace linezolid for the treatment of M. abscessus.
- URI
- https://aac.asm.org/content/61/9/e02752-16https://repository.hanyang.ac.kr/handle/20.500.11754/115149
- ISSN
- 0066-4804; 1098-6596
- DOI
- 10.1128/AAC.02752-16
- Appears in Collections:
- GRADUATE SCHOOL[S](대학원) > BIONANOTECHNOLOGY(바이오나노학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML